Beam Therapeutics Inc.

Beam Therapeutics Inc.(BEAM)股票分析

$23.470

-1.197 (-5.10%)收盤時

Loading chart…
最高
24.560
開盤
24.560
成交量加權均價
23.73
成交量
1.65M
市值
1.97B
最低
23.160
成交金額
39.22M
企業價值/稅息折舊攤銷前利潤(TTM)
-0.16

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

AI 分析 of Beam Therapeutics Inc. (BEAM)

賣出

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

估值指標

Beam Therapeutics Inc.(BEAM)目前預期本益比為 0.00,5 年平均預期本益比為 -7.97。

預期本益比

高估
5 年均值 P/E
-7.97
目前P/E
0.00
高估
-2.96
低估
-12.97

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-4.65
目前EV/EBITDA
-0.16
高估
39.49
低估
-48.80

預期股價營收比

合理
5 年均值 P/S
57.51
目前P/S
40.71
高估
114.81
低估
0.21

Alphio AI 對 BEAM 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BEAM

$14.05

情境價格

基

基準

基準 · 50%BEAM

$12.36

情境價格

悲

悲觀

悲觀 · 25%BEAM

$11.13

情境價格

持有 BEAM 的大戶

A

ARK Investment Management LLC

+ 持有BEAM

+10.03%

3個月報酬率

F

Farallon Capital Management, L.L.C.

+ 持有BEAM

+0.00%

3個月報酬率

C

Casdin Capital, LLC

+ 持有BEAM

-5.77%

3個月報酬率

A

Arch Venture Partners, L.P.

+ 持有BEAM

-21.17%

3個月報酬率

A

Alphabet Inc.

+ 持有BEAM

-23.87%

3個月報酬率

D

Deep Track Capital, LP

+ 持有BEAM

-25.40%

3個月報酬率

事件時間軸

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

10:30:00

Beam Therapeutics Shares Drop 12.7% to $25.88

資訊

BEAM 常見問題 —— 由 Alphio AI 解答

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

apemosaic305 天前

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

展開
alpha_baker2026/10/4

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

展開
perp_sigil2026/10/4

🚀 Top Gainers Alert: $2U2 & $BEAM Are Breaking Out! 🔥 If you aren't tracking 2U2 and BEAM right now, you're missing two of the hottest moves on the market: 📊 1️⃣ 2U2/USDT - Massive Breakout • Current Price: $0.01631 • 24h Surge: +35.80% (24h High: $0.01640) • Technical Setup: After consolidating around $0.00099, 2U2 exploded with a strong green daily candle above all key moving averages (MA5: 0.01131, MA10: 0.00964). Volume has spiked over 64.57M 2U2! 🎮 2️⃣ BEAM/USDT - GameFi Volume Spike • Current Price: $0.002562 • 24h Surge: +20.56% (24h High: $0.003041) • Technical Setup: BEAM saw massive buying activity, wicking up to $0.003041. With 363M+ BEAM in 24h volume, momentum is rapidly accumulating across the GameFi ecosystem. 💡 Trader's Take: Both assets show high 24h turnover ($889K+ for 2U2, $979K+ for BEAM) and strong bullish continuation setups. Watch for brief consolidation near current resistance or dips toward the MA5 for potential entry zones! 📈 Disclaimer: Crypto trading involves high market risk. Always manage risk & NFA.

展開
picoprism2026/10/4

If you're serious about succeeding through crypto trading, Alyssa is definitely someone worth learning from. Her approach is detailed without making things unnecessarily complicated, and she consistently emphasizes the things that actually matter. Understanding the market, managing risk, and staying disciplined. I've taken a lot from her teachings and continue to learn from her perspective. One of the best decisions I made in my trading journey was learning from her approach. I'm only 4 weeks in, and I've made over $73,585 in profits. Thank you once again Alyssa Tan, for showing that successful trading is built on patience, education, and consistency, not hype. $WLD $BEAM $TRX

展開
chrome_nonce2026/10/4

$STRK $QUBIC $BEAM Bitcoin is back on everyone’s radar. 🚀₿ BTC pushed back above the $85K area over the weekend after Friday’s volatility, showing that buyers are still willing to step in when the market gets shaken out. 📈 But don’t confuse momentum with certainty. The bigger story right now is the changing relationship between Bitcoin, equities, Treasury yields and expectations for the Fed. That means October could bring some serious volatility. My approach? Watch the levels, wait for confirmation, and never let FOMO become your trading strategy. 🔥🧠 The next move could be explosive — but risk management comes first.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易